• Something wrong with this record ?

Stratification model based on early postprostatectomy prostate-specific antigen kinetics may help to reduce the risk of overtreatment in candidates for adjuvant radiotherapy

S. Vesely, L. Jarolim, M. Schmidt, J. Do Carmo Silva, K. Duskova, M. Babjuk,

. 2017 ; 51 (2) : 114-119. [pub] 20170224

Language English Country England, Great Britain

Document type Journal Article

Grant support
NV15-33910A MZ0 CEP Register

OBJECTIVE: The aim of this study was to construct a stratification model based on early postoperative kinetics of prostate-specific antigen (PSA) to select the most suitable high-risk patients for early intervention after radical prostatectomy (RP). MATERIALS AND METHODS: The study evaluated 205 men who had undergone RP without any adjuvant treatment. All of the patients had positive surgical margins, extracapsular extension and/or seminal vesicle invasion. The patients underwent multiple ultrasensitive PSA measurements on days 14, 30, 60 and 90 after RP, and subsequently at 3 month intervals. The ability of particular PSA measurements to predict biochemical recurrence (BCR) was assessed using the area under the curve (AUC). A sequential mathematical decision procedure was constructed to create a stratification model. RESULTS: During the median follow-up of 45.9 months, 106 patients (51%) experienced BCR. Prediction of BCR in terms of the AUC for PSA measurements on days 14, 30, 60 and 90 after the surgery was 0.61, 0.70, 0.80 and 0.82, respectively. In the multivariate analysis, only PSA after RP remained as a predictor of progression-free survival (p < 0.001). The stratification model based on calculated cut-off values for PSA on day 30 (0.068 ng/ml) and PSA on day 60 (0.015 ng/ml) reduced the potential overtreatment rate by 37%. CONCLUSIONS: The results imply that ultrasensitive PSA values obtained very early after RP correlate with the presence of recurrent disease in high-risk patients. Incorporating these readily available variables into risk stratification models may help to individualize the administration of adjuvant radiotherapy and thus to minimize overtreatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024915
003      
CZ-PrNML
005      
20201116083702.0
007      
ta
008      
180709s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/21681805.2017.1292545 $2 doi
035    __
$a (PubMed)28635569
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vesely, Stepan $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
245    10
$a Stratification model based on early postprostatectomy prostate-specific antigen kinetics may help to reduce the risk of overtreatment in candidates for adjuvant radiotherapy / $c S. Vesely, L. Jarolim, M. Schmidt, J. Do Carmo Silva, K. Duskova, M. Babjuk,
520    9_
$a OBJECTIVE: The aim of this study was to construct a stratification model based on early postoperative kinetics of prostate-specific antigen (PSA) to select the most suitable high-risk patients for early intervention after radical prostatectomy (RP). MATERIALS AND METHODS: The study evaluated 205 men who had undergone RP without any adjuvant treatment. All of the patients had positive surgical margins, extracapsular extension and/or seminal vesicle invasion. The patients underwent multiple ultrasensitive PSA measurements on days 14, 30, 60 and 90 after RP, and subsequently at 3 month intervals. The ability of particular PSA measurements to predict biochemical recurrence (BCR) was assessed using the area under the curve (AUC). A sequential mathematical decision procedure was constructed to create a stratification model. RESULTS: During the median follow-up of 45.9 months, 106 patients (51%) experienced BCR. Prediction of BCR in terms of the AUC for PSA measurements on days 14, 30, 60 and 90 after the surgery was 0.61, 0.70, 0.80 and 0.82, respectively. In the multivariate analysis, only PSA after RP remained as a predictor of progression-free survival (p < 0.001). The stratification model based on calculated cut-off values for PSA on day 30 (0.068 ng/ml) and PSA on day 60 (0.015 ng/ml) reduced the potential overtreatment rate by 37%. CONCLUSIONS: The results imply that ultrasensitive PSA values obtained very early after RP correlate with the presence of recurrent disease in high-risk patients. Incorporating these readily available variables into risk stratification models may help to individualize the administration of adjuvant radiotherapy and thus to minimize overtreatment.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x krev $7 D009364
650    _2
$a pooperační období $7 D011184
650    _2
$a prostatický specifický antigen $x krev $7 D017430
650    _2
$a prostatektomie $7 D011468
650    _2
$a nádory prostaty $x krev $x radioterapie $x chirurgie $7 D011471
650    _2
$a ROC křivka $7 D012372
650    _2
$a adjuvantní radioterapie $7 D018714
650    _2
$a hodnocení rizik $x metody $7 D018570
650    _2
$a časové faktory $7 D013997
650    _2
$a procedury zbytečné $x statistika a číselné údaje $7 D019564
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jarolim, Ladislav $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
700    1_
$a Schmidt, Marek $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
700    1_
$a Do Carmo Silva, Joana $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
700    1_
$a Duskova, Katerina $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
700    1_
$a Babjuk, Marko $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
773    0_
$w MED00193240 $t Scandinavian journal of urology $x 2168-1813 $g Roč. 51, č. 2 (2017), s. 114-119
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28635569 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20201116083701 $b ABA008
999    __
$a ok $b bmc $g 1317046 $s 1021836
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 51 $c 2 $d 114-119 $e 20170224 $i 2168-1813 $m Scandinavian journal of urology $n Scand J Urol $x MED00193240
GRA    __
$a NV15-33910A $p MZ0
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...